---
canonical_url: https://www.stockexpertai.com/zh/earnings/abbv
last_updated: 2026-05-03T20:44:11.120Z
---

# AbbVie Inc. (ABBV) Q4 FY2026 财报预览

> 此内容由 FMP 实时数据 + Q1 FY2026 财报电话会议记录自动生成。生成时间：2026-05-03T20:44:10.001Z。本工具为教育目的，不构成投资建议。

---

## 快速摘要

| 字段 | 值 | 来源 |
|---|---|---|
| 价格 | $206.60 (▼ -2.23%) | fmp:quote |
| 市值 | $365.4B | fmp:profile |
| 52周区间 | $176.57 – $244.81 | fmp:quote |
| 财报 | 周四 30 7月 | fmp:earnings-history |
| EPS 预期 | $3.73 (+26% YoY) | fmp:earnings-estimate |
| 营收预期 | $16.8B | fmp:earnings-estimate |
| 超预期连胜 | 5/4 | fmp:earnings-history |
| 评级 | C- (overall 1/5) | fmp:ratings |
| 分析师中位数目标价 | $260 (+25.8% upside) | fmp:price-target-consensus |
| MoonshotScore | 56/100 | derived |
| Council | 3/6 bullish | derived |
| 芒格结论 | 低估 | derived |

## AbbVie Inc. — Q4 FY2026 预期

Q4 季度共识：营收 <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$16.8B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>，EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$3.73</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>。连续 5 个季度超出预期<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>。

## 快速概览

**得分：** C- · **立场：** BUY · **Council：** 3/6 · **Moonshot：** 56

= MoonshotScore <strong>56</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="MoonshotScore">[MoonshotScore]</sup> + Council <strong>3/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="Council">[Council]</sup>。Form 4: 0 笔交易<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>。

## 观察列表 (5个指标)

### 1. Fy Eps Guidance Increase

由于业绩强劲，艾伯维将全年调整后每股收益预期提高了 0.12 美元，目前预计调整后每股收益在 14.08 美元至 14.28 美元之间。

> "基于这种强劲的表现，我们将全年调整后每股收益预期提高了 0.12 美元，目前预计调整后每股收益在 14.08 美元至 14.28 美元之间。"
> — Robert Michael, Chairman and Chief Executive Officer, Expectation / Guide · Q1 FY2026

### 2. Rinvoq Growth Expectations

预计 Rinvoq 的全球销售额将达到 102 亿美元，反映了风湿病和胃肠道适应症的强劲表现。

> "Rinvoq 的全球销售额为 102 亿美元，增加了 1 亿美元，反映了风湿病和胃肠道适应症的强劲表现。"
> — Scott Reents, Executive Vice President and Chief Financial Officer, Expectation / Guide · Q1 FY2026

### 3. Neuroscience Revenue Growth

预计神经科学总收入将达到 126 亿美元，增加 1 亿美元，反映了整个投资组合的增长势头。

> "神经科学总收入为 126 亿美元，增加了 1 亿美元，反映了整个投资组合的增长势头。"
> — Scott Reents, Executive Vice President and Chief Financial Officer, Investor Focus · Q1 FY2026

### 4. Skyrizi Ibd Growth

Skyrizi 有望在今年实现克罗恩病和溃疡性结肠炎超过 30% 的全球销售额增长。

> "Skyrizi 在 IBD 方面的表现仍然非常强劲，有望在今年实现克罗恩病和溃疡性结肠炎超过 30% 的全球销售额增长。"
> — Jeffrey Stewart, Executive Vice President, Chief Commercial Officer, Investor Focus · Q1 FY2026

### 5. Us Rd Investment

作为艾伯维未来十年投资 1000 亿美元用于美国研发和资本投资承诺的一部分，该公司最近宣布建设多个新的制造基地。

> "最后，作为艾伯维未来十年投资 1000 亿美元用于美国研发和资本投资承诺的一部分，我们最近宣布建设多个新的制造基地。"
> — Robert Michael, Chairman and Chief Executive Officer, Investor Focus · Q1 FY2026


## MoonshotScore 支柱

| 支柱 | 得分 | 水平 | 证据 |
|---|---|---|---|
| 营收增长 | 0.0 | weak | Q1 vs Q2: 负增长 (-%2.7，收缩) |
| 毛利率 | 8.0 | strong | Q1: 极高毛利率 (%83.5，软件/云服务级别) |
| 经营杠杆 | 3.0 | weak | 营业利润率非常强劲 (%31.6，规模杠杆) |
| 现金流储备 | 10.0 | strong | FCF 非常强劲 ($4.9B，是资本支出的 14.9 倍以上) |
| 研发投入强度 | 7.0 | strong | 平衡的研发投资 (%11.2) |
| 价格动能 | 4.0 | medium | RSI 48.9 平衡，50日均线 之下 |
| 新闻情绪 | 7.0 | strong | 强烈买入共识 (73%) |

**公式:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7视角)

| 名称 | 立场 | 背景 |
|---|---|---|
| Ray Dalio | bull | 宏观 · 目标上涨空间 +25.8% |
| Ken Griffin | bear | 资金流 · 50日均线 之下 |
| Jim Simons | neutral | 量化 · RSI 49 |
| Klarman | bull | 价值 · 目标上涨空间 +25.8% |
| Buffett | neutral | 质量 · ROE 评分 1/5 |
| Munger | bull | 估值 · 目标上涨空间 +25.8% |

**公式:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## 芒格视角

- **结论:** 低估
- **财务健康:** Weak
- **安全边际:** Strong
- **利息覆盖率:** Adequate
- **ROIC vs WACC:** Tight

**公式:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## 技术水平

- **RSI(14):** 48.9 — dengeli — yön sinyali zayıf
- **50日均线:** $215 — hisse %3.7 altında — kısa vadeli direnç
- **200日均线:** $218 — hisse %5.2 altında — uzun vadeli baskı
- **成交量 (10日):** -18%

## 历史表现 (4个季度)

| 季度 | 实际 EPS | 预期 EPS | 结果 | 反应 |
|---|---|---|---|---|
| Q2 FY25 | $2.97 | $2.88 | BEAT | +3.3% |
| Q3 FY25 | $1.86 | $1.77 | BEAT | -2.8% |
| Q4 FY25 | $2.71 | $2.65 | BEAT | +0.9% |
| Q1 FY26 | $2.65 | $2.59 | +2.3% EPS | +3.6% |

Q1 (2026年4月29日): EPS $2.65 vs 预期 $2.59<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>，超出 +%2.3。D+1 走势：+3.6%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>。尽管超出预期，但股价下跌 — 市场对指引而非数据做出反应。

## 3种情景

### 情景 A · 超预期
**Q4 EPS > $3.73 + 资本支出纪律**

阈值：EPS > $3.73<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>。

目标：突破中位数目标价 $260<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>；高目标价 $294<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> 为上限。

### 情景 B · 符合预期
**EPS ≈ $3.73 + CapEx < $329.0M**

阈值：EPS ≈ $3.73<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>，Q4 资本支出 < $329.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>。

目标：在当前价 $207<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> 与中位数目标价 $260<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup> 区间内盘整。

### 情景 C · 未达预期
**EPS < $3.62 或 CapEx ≥ $329.0M**

阈值：EPS < $3.62<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>。

目标：当前价 $207 低于 200日均线 $218<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>，若持续拒绝，则激活 $185<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> 支撑位。

## 风险提示

### {{segment}} 低于阈值
Q1 季度：EPS $2.65 vs 预期 $2.59<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>，超出预期，股价 D+1 +3.6%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>。

### 对 OpenAI 的依赖
Q1 财报电话会议中未披露 RPO/积压集中度。

### 内幕交易
Form 4 数据已在表格中标记 — 本页面不为此股票生成假设。

| 高管 | 操作 | 金额 | 日期 |
|---|---|---|---|


**净额:** — (0 笔交易 · 0 笔卖出 · 0 笔买入) · Q1 FY26

### 资本支出冲击
Q1 季度资本支出 $329.0M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>。 Q1 营业利润率 %31.6<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — Q4 的这一水平对资本支出修订风险敏感。

## 华尔街共识

- **中位数目标价:** $260 (+25.8% upside vs current $207)
- **高 / 低:** $294 / $223
- **买入 / 持有 / 卖出:** 24 / 9 / 0
- **分析师数量:** 10 (上一季度), 75 历史总数

## 额外财报电话会议洞察

### 1. skyrizi_psoriatic_leadership

**主张:** Skyrizi maintains its leadership in the psoriatic disease market, holding a significant market share over all biologics and oral treatments.

**证据 (会议记录):** "We continue to demonstrate exceptional performance across psoriatic disease, where we are gaining share and have clear leadership over all biologics and orals by a very wide margin."

**数据:** —

### 2. skyrizi_ibd_growth

**主张:** Skyrizi is on track to deliver more than 30% global sales growth across Crohn's disease and ulcerative colitis this year.

**证据 (会议记录):** "Performance also remains very robust in IBD, where Skyrizi is on track to deliver more than 30% global sales growth across Crohn's disease and ulcerative colitis this year."

**数据:** 30%

### 3. rinvoq_growth_expectations

**主张:** Rinvoq global sales are expected to reach $10.2 billion, reflecting strong performance in the room and gastro indications.

**证据 (会议记录):** "Rinvoq global sales of $10.2 billion, an increase of $100 million, reflecting strong performance in the room and gastro indications."

**数据:** $10.2 billion, $100 million

### 4. neuroscience_revenue_growth

**主张:** Total Neuroscience revenues are expected to reach $12.6 billion an increase of $100 million, reflecting momentum across the portfolio.

**证据 (会议记录):** "Total Neuroscience revenues of $12.6 billion an increase of $100 million, reflecting momentum across the portfolio."

**数据:** $12.6 billion, $100 million

### 5. fy_eps_guidance_increase

**主张:** AbbVie is raising its full year adjusted earnings per share guidance by $0.12 and now expects adjusted EPS between $14.08 and $14.28 due to strong performance.

**证据 (会议记录):** "Based on this strong performance, we are raising our full year adjusted earnings per share guidance by $0.12 and now expect adjusted EPS between $14.08 and $14.28."

**数据:** $0.12, $14.08, $14.28

### 6. us_rd_investment

**主张:** As part of AbbVie's $100 billion commitment to U.S. R&D and capital investments over the next decade, the company recently announced construction of several new manufacturing sites.

**证据 (会议记录):** "Lastly, as part of AbbVie's $100 billion commitment to U.S. R&D and capital investments over the next decade, we recently announced construction of several new manufacturing sites."

**数据:** $100 billion


---

*数据来源：FMP (实时查询，2026-05-03)，Q1 FY2026 财报电话会议记录 (由 Gemini 2.0 Flash 翻译成中文)。本工具为教育目的，不构成投资建议。*